



**Proteomics International**

LABORATORIES LTD

**ASX release**

**31 January 2023**

**ASX code: PIQ**

## **Letter of intent with Sonic Healthcare USA extended**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that it has extended the term of its letter of intent (LOI) with Sonic Healthcare USA, Inc. (a division of Sonic Healthcare Limited; ASX: SHL) (Sonic Healthcare USA) until 28 February 2023.

The binding and exclusive LOI, initially signed in August, provides for entering into an Exclusive Licence Agreement for use of Proteomics International's PromarkerD predictive test for diabetic kidney disease in the United States by Sonic Healthcare USA [ASX: 9 August 2022]. Many of the key terms of the agreement hinged on the granting of a new dedicated CPT PLA reimbursement code for PromarkerD which was achieved and published by the American Medical Association at the beginning of January 2023<sup>1</sup> [ASX: 3 January]. The extension provides both parties the further necessary time to finalise the agreement.

Both parties continue to work diligently toward achieving a successful roll-out of PromarkerD across the USA and to formalise milestone events and timelines in relation to the commercialisation process.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

---

<sup>1</sup> [www.ama-assn.org/practice-management/cpt/cpt-pla-codes](http://www.ama-assn.org/practice-management/cpt/cpt-pla-codes)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)